Horizon Blue Cross Blue Shield of New Jersey

11/16/2026 | Press release | Distributed by Public on 11/16/2026 00:26

Medical Injectables Program Update: December 2026

We are making the following changes to our Medical Injectables Program (MIP) as part of our commitment to helping ensure that the medications provided to our members are medically necessary and cost effective.

INJECTABLE MEDICATIONS SUBJECT TO MEDICAL NECESSITY AND APPROPRIATENESS REVIEW (MNAR)

New Codes/Drugs Subject to MNAR

For services rendered on and after December 24, 2026, Prime Therapeutics Management will conduct MNAR for the following injectable medications as part of the MIP.

BRAND NAME GENERIC NAME HCPCS NATIONAL DRUG CODE
Fayuvi rebisufligene etisparvovec-hopf J3590 69794-0301-05, 69794-0302-06, 69794-0303-08, 69794-0304-09, 69794-0305-11, 69794-0306-12, 69794-0307-14, 69794-0308-15, 69794-0309-18, 69794-0310-21, 69794-0311-24, 69794-0312-27, 69794-0313-30, 69794-0314-33, 69794-0315-36, 69794-0316-39, 69794-0317-42, 69794-0318-45, 69794-0319-48, 69794-0320-51, 69794-0321-54, 69794-0322-57, 69794-0323-60, 69794-0324-63, 69794-0325-69, 69794-0326-75, 69794-0327-81, 69794-0328-87, 69794-0329-93, 69794-0330-99, 69794-0331-05
ISEMBYLD apitegromab-mstn J3590 84717-0150-01
Published on: November 16, 2026, 00:49 a.m. ET
Last updated on: November 16, 2026, 00:52 a.m. ET
Horizon Blue Cross Blue Shield of New Jersey published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 16, 2026 at 06:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]